Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Depreciation & Amortization (CF): 2009-2025

Historic Depreciation & Amortization (CF) for Cytokinetics (CYTK) over the last 17 years, with Sep 2025 value amounting to $2.7 million.

  • Cytokinetics' Depreciation & Amortization (CF) rose 11.12% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.6 million, marking a year-over-year decrease of 28.45%. This contributed to the annual value of $9.5 million for FY2024, which is 19.85% down from last year.
  • Per Cytokinetics' latest filing, its Depreciation & Amortization (CF) stood at $2.7 million for Q3 2025, which was up 17.24% from $2.3 million recorded in Q2 2025.
  • In the past 5 years, Cytokinetics' Depreciation & Amortization (CF) registered a high of $6.3 million during Q4 2023, and its lowest value of $462,000 during Q3 2021.
  • Over the past 3 years, Cytokinetics' median Depreciation & Amortization (CF) value was $2.3 million (recorded in 2024), while the average stood at $2.6 million.
  • In the last 5 years, Cytokinetics' Depreciation & Amortization (CF) skyrocketed by 282.09% in 2023 and then slumped by 62.38% in 2024.
  • Cytokinetics' Depreciation & Amortization (CF) (Quarterly) stood at $734,000 in 2021, then surged by 125.89% to $1.7 million in 2022, then soared by 282.09% to $6.3 million in 2023, then plummeted by 62.38% to $2.4 million in 2024, then climbed by 11.12% to $2.7 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $2.7 million for Q3 2025, versus $2.3 million for Q2 2025 and $2.3 million for Q1 2025.